In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?

Executive Summary

Several new drugs for multiple sclerosis could launch within the next two years, but amid escalating drug costs, payors are taking a harder look at the therapeutic category. New drugs will face increasing reimbursement hurdles, as payors implement the first prior authorization and step therapy protocols and look for ways to implement further cost reductions.


Related Content

Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
Fast Forward And Myelin Repair Foundation: Two Routes To New MS Drugs
Third Trial For Teva’s Laquinimod Hinges On SPA From FDA
Sanofi Targets 18 Drug Launches From 2012 To 2015
How To Withdraw A Drug: FDA’s Final Decision on Avastin
Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
Oral Molecules In An Injectable World: What Developers Need To Do Now
The Lovenox Benchmark: Copaxone "Far More Complex," Teva Argues In Anti-Generic Petition
Launching Ampyra: What Drug Companies Can Learn From The Experience
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts